Aytu Biopharma, Inc.
AYTU
$2.18
$0.010.46%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 14.40% | 111.98% | 70.87% | 74.46% | 7.08% |
| Total Depreciation and Amortization | -20.04% | -22.55% | -26.25% | -24.51% | -23.71% |
| Total Amortization of Deferred Charges | -81.91% | -78.86% | -59.35% | -32.67% | 6.80% |
| Total Other Non-Cash Items | -12.44% | -122.90% | -119.53% | -87.68% | 66.06% |
| Change in Net Operating Assets | 10.85% | -222.63% | 1,133.46% | -378.94% | -16.00% |
| Cash from Operations | -39.55% | -163.07% | -88.99% | -162.16% | 72.94% |
| Capital Expenditure | 30.70% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 165.56% | 161.12% | 132.34% | 100.00% |
| Cash from Investing | -678.12% | 194.00% | 210.64% | 154.47% | -181.20% |
| Total Debt Issued | -38.37% | 426.34% | 527.24% | 467.50% | -- |
| Total Debt Repaid | 88.19% | -627.49% | -448.80% | -487.96% | -570.16% |
| Issuance of Common Stock | 328.04% | 27.63% | -17.29% | -32.80% | -77.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -113.63% | -190.53% | 6.60% | 82.64% | 34.86% |
| Cash from Financing | 1,323.69% | 145.49% | 95.58% | 132.12% | -114.23% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 467.44% | -373.15% | 3,003.57% | 103.74% | -182.18% |